2026-06-08T03:45:30Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/926182025-03-10T13:33:21Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Ochoa-Grullón, Juliana author Benavente Cuesta, Celina author Pérez López, César author Peña Cortijo, Ascensión author Mateos-Aparicio Morales, Gregoria author Fernández Arquero, Miguel author Recio Hoyas, María José author Sánchez-Ramón, Silvia author 2020 An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab responses to pneumococcal and Salmonella typhi pure polysaccharide immunization in a cohort of 42 HM patients and 24 healthy-controls. Pre-post specific Ab concentrations were measured by ELISA at 4 weeks. Globally, significantly lower Typhim Vi (TV) seroprevalence (9%) compared to 23-valent pneumococcal polysaccharide vaccine (PPV) (76%) (p <0.001) was observed. TV non responders (88%) were higher than PPV non responders (62%) (p <0.0001) and correlated better to infectious history. By ROC analysis, pre-post 5-fold TV increase was the best cut-off to discriminate HM with recurrent infections and controls (sensitivity 91%, specificity 100%). Despite the small sample cohort, our results suggest that specific anti-S typhi Ab response is a useful complementary assay in the diagnosis and management decision of SID to HM. Ochoa-Grullón J, Benavente Cuesta C, Pérez López C, Peña Cortijo A, Rodríguez de la Peña A, Álvarez Carmona A, Mateo Morales M, Llano-Hernández K, Williams LJ, Rodríguez de Frías E, Guevara-Hoyer K, Cordero Torres G, Orte C, Fernández-Arquero M, Fernández-Paredes L, Serrano-García I, Recio MJ, Pérez de Diego R, Martínez R, Sánchez-Ramón S. Clin Immunol. 2020 Jan;210:108307. 1521-6616 10.1016/j.clim.2019.108307 https://hdl.handle.net/20.500.14352/92618 https://doi.org/10.1016/j.clim.2019.108307 Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies